DMAC DiaMedica Therapeutics
- 4.500
- +0.210+4.90%
- 4.600
- +0.100+2.22%
DiaMedica Therapeutics News
DiaMedica Therapeutics | 10-Q: Q2 2024 Earnings Report
DiaMedica Therapeutics | 8-K: DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results
DiaMedica Therapeutics | EFFECT: Others
DiaMedica Therapeutics | 424B3: Prospectus
DiaMedica Therapeutics | CORRESP: CORRESP
DiaMedica Therapeutics | UPLOAD: Others
DiaMedica Therapeutics | S-3: Registration statement for specified transactions by certain issuers
DiaMedica Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-John Fichthorn(5.2%),Dialectic Life Sciences SPV LLC(5.1%), etc.
DiaMedica Therapeutics | D: Filing D
DiaMedica Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
DiaMedica Therapeutics | 4: Statement of changes in beneficial ownership of securities-10% Owner Von Koch Thomas
DiaMedica Therapeutics | 4: Statement of changes in beneficial ownership of securities-10% Owner STAHLBERG JAN
DiaMedica Therapeutics | 8-K: Current report
DiaMedica Therapeutics | 8-K: Current report
DiaMedica Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Wambeke David J.
DiaMedica Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Cundari Dominic R
DiaMedica Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kellen Scott
DiaMedica Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Pauls Dietrich John
DiaMedica Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Semba Charles Pauling
DiaMedica Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Pilnik Richard D.
Analysis
Price Target
No Data
No Data